New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
06:11 EDTMRK, NVO, BMYFDA eases worries regarding certain diabetes medications, AP says
The federal Food and Drug Administration and its European counterpart started reviews last year of diabetes drugs which include Merck's (MRK) Januvia and Janumet, Novo Nordisk's (NVO) Victoza and Bristol-Myers Squibb's (BMY) Byetta and Bydureon, reported the Associated Press. Both U.S. and European regulators have found no evidence of a link between these drugs and pancreas problems or pancreatic cancer. Reference Link
News For MRK;NVO;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 30, 2014
08:16 EDTMRKTetraphase price target raised to $32 from $20 at JMP Securities
Subscribe for More Information
07:47 EDTNVOJacobs Engineering receives pharmaceuticals pilot plant contract from Novo Nordisk
Subscribe for More Information
07:30 EDTNVOSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 29, 2014
08:22 EDTBMYBristol-Myers says EMA validates MAA for Nivolumab in NSCLC
Bristol-Myers Squibb announced that the European Medicines Agency has validated for review the Marketing Authorization Application for nivolumab in non-small cell lung cancer– the first completed regulatory submission for a PD-1 immune checkpoint inhibitor in this tumor type. The MAA submitted to the EMA in lung cancer is based on data from the Phase 2 study of nivolumab in third-line pre-treated squamous cell NSCLC. In addition to the MAA for lung cancer in the E.U., the company previously announced that it has initiated a rolling submission with the FDA for Opdivo in third-line pre-treated squamous cell NSCLC and expects to complete the submission by year-end.
07:26 EDTMRK, BMYInforma Business Information to hold a conference
Subscribe for More Information
05:44 EDTMRKMerck announces early data from investigational use of KEYTRUDA
Merck announced the first presentation of data on the investigational use of KEYTRUDA, the company’s anti-PD-1 therapy, in PD-L1 positive, advanced urothelial cancer. The early findings presented showed a confirmed overall response rate of 24% with KEYTRUDA as monotherapy, as measured by RECIST v1.1, central review including a complete response rate of 10%. At the time of analysis, response durations ranged from 16+ to 40+ weeks with six of the seven responders continuing on therapy. In the ongoing study, 64% of patients screened had tumors that were determined to be positive for PD-L1 expression.
05:32 EDTBMYBristol-Myers announces positive Phase 3 data for Opdivo
Subscribe for More Information
September 28, 2014
12:53 EDTMRKMerck announces first presentation of data on investigational use of KEYTRUDA
Subscribe for More Information
September 26, 2014
16:20 EDTBMYBristol-Myers announces multiple regulatory milestones for Opdivo in U.S., EU
Subscribe for More Information
08:31 EDTMRKLigand, Merck receive approval for NOXAFIL
Subscribe for More Information
September 23, 2014
12:10 EDTBMYBristol-Myers to build 650,000 square foot campus in Lawrenceville, NJ
Subscribe for More Information
07:33 EDTMRKOphthotech names Michael Atieh as EVP, Chief Financial and Business Officer
Ophthotech Corporation (OPHT) announced that Michael G. Atieh has been named EVP, Chief Financial and Business Officer and Treasurer effective September 30. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the company of his intention to retire effective September 30. Atieh spent the majority of his career in the pharmaceutical industry with Merck and Co (MRK), where he held various senior level positions over a 20 year period including Senior Vice President-Merck Medco Managed Care, Vice President-U.S. Human Health, Vice President-Public Affairs, Vice President-Government Relations, and Treasurer.
September 22, 2014
07:21 EDTBMYEBD Group to hold a conference
Subscribe for More Information
06:51 EDTMRKMerck to host conference call
Subscribe for More Information
September 18, 2014
14:20 EDTNVONovo Nordisk announces EC marketing authorisation for Xultophy
Subscribe for More Information
13:13 EDTNVONovo Nordisk Ryzodeg does not meet primary endpoint in phase 3b trial
Subscribe for More Information
08:48 EDTMRKNeogen's dairy genomic program to be marketed by Merck
Subscribe for More Information
September 17, 2014
09:33 EDTMRKMerck announced positive results from Phase 3 data for omarigliptin
Subscribe for More Information
08:31 EDTMRKMerck, Sun Pharma enter into licensing agreement for Tildrakizumab
Merck and Sun Pharmaceutical Industries, through their respective subsidiaries,announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80M. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales. The transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.
07:43 EDTBMYBofA/Merrill to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use